- BioSig Technologies ( NASDAQ: BSGM ) has s igned a research agreement with the Cleveland Clinic to examine additional clinical applications for the intracardiac signals acquired by its PURE EP System.
- Cleveland Clinic will conduct physician-initiated research investigating PURE EP's potential to address common limitations of signal processing and signal use expansion during— but not limited to— electrophysiology ablation procedures.
- BioSig ( BSGM ) said the results from the research could lead to new clinical workflow methods influencing the ablation process for many arrhythmia types.
- Seeking Alpha Quant Rating views BioSig ( BSGM ) as a hold with high marks for revisions and momentum .
For further details see:
BioSig in agreement with Cleveland Clinic to boost digital signal processing applications